Tofacitinib: Read this before starting it

Tofacitinib is a relatively new oral immunomodulatory medication offering renewed hope for patients with treatment-resistant autoimmune and inflammatory conditions such as rheumatoid arthritis, ulcerative colitis, and psoriatic arthritis. Due to its immunosuppressive potential, Tofacitinib is prescribed only when the therapeutic benefits outweigh the associated risks. Patients should be well-informed about its mechanism, approved indications, and potential side effects before initiating therapy.

Mechanism of Action

Tofacitinib is a Janus kinase (JAK) inhibitor, specifically targeting JAK1 and JAK3 enzymes. These kinases play a crucial role in the signaling pathway of type I and type II cytokines. By blocking these signals, Tofacitinib reduces the inflammatory response associated with autoimmune diseases. This targeted mechanism makes it particularly effective in conditions where cytokine-driven inflammation is central to disease pathogenesis.

FDA-Approved Indications

Tofacitinib is currently approved by the U.S. FDA for the following conditions—primarily in cases unresponsive to conventional therapies:

• Rheumatoid Arthritis

• Ulcerative Colitis

• Psoriatic Arthritis

• Polyarticular Course Juvenile Idiopathic Arthritis (in patients ≥2 years of age)

Off-Label and Investigational Use

Though not formally approved for dermatological use, Tofacitinib is gaining traction in dermatology for its JAK-inhibiting properties. Emerging evidence supports its use in:

• Moderate to severe Psoriasis and Psoriatic Arthritis

• Severe Alopecia Areata, including Alopecia Totalis and Universalis

• Atopic Dermatitis

• Vitiligo

Its role in dermatological conditions remains largely off-label and is typically reserved for cases where standard therapies have failed.

Common Side Effects

These side effects are generally mild to moderate and often manageable with monitoring:

• Upper respiratory tract infections

• Headache

• Diarrhea

• Reactivation of latent viral infections, particularly Herpes Zoster

• Laboratory abnormalities: changes in hemoglobin, white blood cell counts, liver enzymes, and lipid profiles

Serious and Less Common Adverse Events

While rare, the following complications require immediate medical attention:

• Severe infections: Tuberculosis, systemic fungal infections

• Malignancies: Increased risk of lymphomas, skin cancers, and solid organ tumors

• Gastrointestinal: Risk of perforation, obstruction, or bleeding

• Hypersensitivity reactions: Urticaria, angioedema

• Hypertension

• Neurological complications

• Musculoskeletal symptoms: Joint pains, back pain, limb discomfort

Tofacitinib Dosing and Use in Children

Recommended Dosage in Adults

Treatment with Tofacitinib typically begins at 5 mg twice daily. In cases where patients do not show an adequate clinical response, physicians may escalate the dose to 10 mg twice daily. However, it is important to note that higher doses are associated with an increased risk of adverse effects, and any dose adjustments should be made under close medical supervision with regular monitoring of blood parameters and clinical status.

Is Tofacitinib Safe for Children?

The U.S. Food and Drug Administration (FDA) approved Tofacitinib in 2020 for use in children aged 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). This approval marks a significant step in expanding treatment options for pediatric rheumatologic conditions.

That said, long-term safety data in children remain limited, as the duration of pediatric use is relatively recent. Available case series and early clinical experience suggest that Tofacitinib is generally well tolerated in children, with minimal side effects reported. However, due to the lack of long-term safety evidence, its use in pediatric populations should be reserved for cases where first-line therapies have failed and where the potential benefits clearly outweigh the risks.

Pre-Treatment Screening and Monitoring

Tofacitinib modulates immune function by inhibiting specific cytokine pathways, which, while beneficial in controlling inflammation, also increases the risk of infections, malignancies, and cardiovascular complications. Therefore, comprehensive screening and ongoing monitoring are essential before and during treatment.

1. Infection and Cancer Screening

Due to its immunosuppressive action, Tofacitinib may impair the body's natural defenses, predisposing patients to opportunistic infections and malignancies. As a precaution, clinicians perform thorough evaluations to rule out latent infections and assess oncologic risk.

Infection Screening (Baseline):

• Tuberculosis: Chest X-ray and Mantoux test (especially critical in high-prevalence regions like India)

• Hepatitis B Surface Antigen (HBsAg)

• Hepatitis C Virus (Anti-HCV)

• HIV Screening

2. Cardiovascular Risk Assessment

The U.S. FDA has issued warnings about an increased risk of serious cardiovascular events, including heart attack, stroke, venous thromboembolism, and mortality, particularly in high-risk individuals.

Your healthcare provider will evaluate:

• History of smoking

• Past or present heart disease, stroke, or blood clots

• Other cardiovascular risk factors

3. Gastrointestinal Screening

Tofacitinib should be used with caution in patients with a history of diverticulitis, as it has been associated with gastrointestinal perforation. Concomitant use of NSAIDs (painkillers) and oral corticosteroids further increases this risk and should generally be avoided.

4. Laboratory Monitoring

Regular blood investigations are necessary to detect adverse effects early and ensure continued safety during therapy.

Baseline and Ongoing Tests (Typically Monthly):

• Complete Blood Count (CBC)

• Kidney Function Tests (KFT)

• Liver Function Tests (LFT)

• Lipid Profile

Precautions While Taking Tofacitinib

Patients on Tofacitinib should adhere to the following safety measures to minimize risks:

• Avoid contact with individuals who have active infections

• Do not take live vaccines during treatment

• Consult your doctor before starting any new medication or herbal supplements

• Practice strict personal hygiene to reduce infection risk

• Do not miss scheduled follow-up visits and laboratory tests

• Report any unusual symptoms immediately, including:

  • Fever

  • Chest or abdominal pain

  • Unexplained bleeding or bruising

  • Skin rashes or nodules

  • Joint pains

  • Appearance of new lumps

Key Takeaway

Tofacitinib represents a significant advancement in the treatment of autoimmune diseases, including dermatological conditions. However, its use must be individualized, closely monitored, and reserved for patients who do not respond to conventional therapies. Prior to starting this medication, a thorough discussion with your healthcare provider regarding risks, benefits, and regular monitoring protocols is essential.